BioVaxys Engages Life Sciences Public Relations and Market Communications Firm 6 Degrees
BioVaxys Technology Corp. announced the engagement of 6 Degrees, a communications firm, to enhance its strategic communications, public and media relations, and social media efforts. The President & COO, Kenneth Kovan, stated that this decision aligns with BioVaxys's growth and aims to increase public awareness. BioVaxys is focused on developing vaccines and diagnostics for viral and oncology applications, including a SARS-CoV-2 vaccine and cancer therapies. The company holds two US patents related to its cancer vaccine and has pending applications for its COVID-19 vaccine technologies.
- Engagement of 6 Degrees to improve strategic communications.
- Company has two issued US patents for its cancer vaccine.
- Plans for a clinical trial of a SARS-CoV-2 vaccine.
- Forward-looking statements indicate uncertainty in vaccine effectiveness and regulatory approvals.
- Need for additional capital to fund clinical trials.
VANCOUVER, British Columbia, Sept. 20, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") announced today that it has engaged life sciences and healthcare communications firm 6 Degrees to handle its strategic communications planning, public and media relations, and social media presence. Located in the US biopharmaceutical hub of New York/New Jersey/Pennsylvania, 6 Degrees has worked with an extensive roster of companies ranging from emerging publicly traded biotech companies to Fortune 500 pharmaceutical companies.
BioVaxys President & Chief Operating Officer Kenneth Kovan commented, "As BioVaxys continues to grow and advance its programs, it seemed logical for us to expand the range and scope of our market communications activities. We believe 6 Degrees has the relationships and expertise to further raise our public awareness and visibility."
About BioVaxys Technology Corp.
Based in Vancouver, BioVaxys Technology Corp. (www.biovaxys.com) is a British Columbia-registered, clinical stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The Company is advancing a SARS-CoV-2 vaccine based on its haptenized viral protein technology, and is planning a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors that will initially be developed for Stage III/Stage IV ovarian cancer. Also in development is CoviDTH®, a diagnostic for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19. BioVaxys has two issued US patents and two patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies. BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF).
ON BEHALF OF THE BOARD
Signed "James Passin"
James Passin, CEO
+1 646 452 7054
Media Contacts BioVaxys Technology Corp.
Gina Cestari, Senior VP
6 Degrees Public Relations
+1 917 797 7904
gcestari@6degreespr.com
Cautionary Statements Regarding Forward Looking Information
This press release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable Canadian and United States securities legislation including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein, without limitation, statements relating the future operating or financial performance of the Company, are forward looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. Forward-looking statements in this news release relate to, among other things, completion of the murine model study, regulatory approval for a Phase I study of its BVX-0320 Vaccine Candidate in humans and the overall development of BioVaxys' vaccines, including any haptenized SARS-Cov-2 protein vaccine. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements.
These forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVayxs' vaccines will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, uncertainty about whether its autologous cell vaccine immunotherapy can be developed to produce safe and effective products and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties.
The Company does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
ON BEHALF OF THE BOARD
Signed "James Passin"
James Passin, CEO
+1 646 452 7054
Media Contacts BioVaxys Technology Corp.
Gina Cestari, Senior VP
6 Degrees Public Relations
+1 917 797 7904
gcestari@6degreespr.com
Logo - https://mma.prnewswire.com/media/1436186/BIOVAXYS_Corporate_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/biovaxys-engages-life-sciences-public-relations-and-market-communications-firm-6-degrees-301379875.html
SOURCE BioVaxys Technology Corp.
FAQ
What recent announcement was made by BioVaxys Technology Corp.?
What is the focus of BioVaxys Technology Corp.?
What are the ticker symbols for BioVaxys in different markets?
What patents does BioVaxys Technology Corp. hold?
What are the potential risks mentioned in the BioVaxys press release?
